ScinoPharm Taiwan (1789), an all-round niche pharmaceutical company, has been actively investing in business transformation and strengthening the internal integration of resources in recent years, and the results have gradually emerged. Following the cooperation with Baxter and the successful launch of injectable formulation of adjuvant antiemetic drugs for chemotherapy patients in the U.S. market, another good news has rung out from ScinoPharm in the promotion of its injectable formulation business. ScinoPharm’s first self-developed anticoagulant injectable formulation with highly advanced synthesis technology has launched in the U.S., and ScinoPharm has now accumulated a total of three injectable formulation products that are marketed in the U.S.

This year, ScinoPharm continues to be faced with high-intensity challenges of large-scale mergers and acquisitions in the global pharmaceutical market and ongoing reduction in drug prices, as well as the increasing influence of China and India on the global pharmaceutical industry. Tsung-Ming Su, General Manager of ScinoPharm Taiwan, said: “The market share of existing API products must be kept stable, while the next phase of product development and layout should be carried out early, and the business driving force of the injectable formulation business should be strengthened to establish a more diverse development model.” By utilizing a multi-angle flexible business strategy, ScinoPharm can be fully prepared to face various challenges.